246 related articles for article (PubMed ID: 35885544)
1. The Mesenchymal Niche in Myelodysplastic Syndromes.
Friedrich C; Kosmider O
Diagnostics (Basel); 2022 Jul; 12(7):. PubMed ID: 35885544
[TBL] [Abstract][Full Text] [Related]
2. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
Li AJ; Calvi LM
Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
4. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
5. Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.
Balderman SR; Li AJ; Hoffman CM; Frisch BJ; Goodman AN; LaMere MW; Georger MA; Evans AG; Liesveld JL; Becker MW; Calvi LM
Blood; 2016 Feb; 127(5):616-25. PubMed ID: 26637787
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
7. Inappropriate Notch activity and limited mesenchymal stem cell plasticity in the bone marrow of patients with myelodysplastic syndromes.
Varga G; Kiss J; Várkonyi J; Vas V; Farkas P; Pálóczi K; Uher F
Pathol Oncol Res; 2007; 13(4):311-9. PubMed ID: 18158566
[TBL] [Abstract][Full Text] [Related]
8. Bone marrow mesenchymal stromal cell-derived extracellular matrix displays altered glycosaminoglycan structure and impaired functionality in Myelodysplastic Syndromes.
Bains AK; Behrens Wu L; Rivière J; Rother S; Magno V; Friedrichs J; Werner C; Bornhäuser M; Götze KS; Cross M; Platzbecker U; Wobus M
Front Oncol; 2022; 12():961473. PubMed ID: 36158640
[TBL] [Abstract][Full Text] [Related]
9. Identifying Bone Marrow Microenvironmental Populations in Myelodysplastic Syndrome and Acute Myeloid Leukemia.
Kaszuba CM; Rodems BJ; Sharma S; Franco EI; Ashton JM; Calvi LM; Bajaj J
J Vis Exp; 2023 Nov; (201):. PubMed ID: 38009736
[TBL] [Abstract][Full Text] [Related]
10. Aging- and Senescence-associated Changes of Mesenchymal Stromal Cells in Myelodysplastic Syndromes.
Mattiucci D; Maurizi G; Leoni P; Poloni A
Cell Transplant; 2018 May; 27(5):754-764. PubMed ID: 29682980
[TBL] [Abstract][Full Text] [Related]
11. Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.
Fattizzo B; Giannotta JA; Barcellini W
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751628
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic syndrome hematopoietic stem cell.
Li J
Int J Cancer; 2013 Aug; 133(3):525-33. PubMed ID: 23047726
[TBL] [Abstract][Full Text] [Related]
13. MDS cells impair osteolineage differentiation of MSCs via extracellular vesicles to suppress normal hematopoiesis.
Hayashi Y; Kawabata KC; Tanaka Y; Uehara Y; Mabuchi Y; Murakami K; Nishiyama A; Kiryu S; Yoshioka Y; Ota Y; Sugiyama T; Mikami K; Tamura M; Fukushima T; Asada S; Takeda R; Kunisaki Y; Fukuyama T; Yokoyama K; Uchida T; Hagihara M; Ohno N; Usuki K; Tojo A; Katayama Y; Goyama S; Arai F; Tamura T; Nagasawa T; Ochiya T; Inoue D; Kitamura T
Cell Rep; 2022 May; 39(6):110805. PubMed ID: 35545056
[TBL] [Abstract][Full Text] [Related]
14. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stromal cells in myeloid malignancies.
Schroeder T; Geyh S; Germing U; Haas R
Blood Res; 2016 Dec; 51(4):225-232. PubMed ID: 28090484
[TBL] [Abstract][Full Text] [Related]
16. The bone marrow stem stromal imbalance--a key feature of disease progression in case of myelodysplastic mouse model.
Das M; Chatterjee S; Basak P; Das P; Pereira JA; Dutta RK; Chaklader M; Chaudhuri S; Law S
J Stem Cells; 2010; 5(2):49-64. PubMed ID: 22049615
[TBL] [Abstract][Full Text] [Related]
17. The mesenchymal compartment in myelodysplastic syndrome: Its role in the pathogenesis of the disorder and its therapeutic targeting.
Pontikoglou CG; Matheakakis A; Papadaki HA
Front Oncol; 2023; 13():1102495. PubMed ID: 36761941
[TBL] [Abstract][Full Text] [Related]
18. Biologic characteristics of bone marrow mesenchymal stem cells in myelodysplastic syndromes.
Kastrinaki MC; Pontikoglou C; Klaus M; Stavroulaki E; Pavlaki K; Papadaki HA
Curr Stem Cell Res Ther; 2011 Jun; 6(2):122-30. PubMed ID: 20528751
[TBL] [Abstract][Full Text] [Related]
19. Immune Dysregulation and Recurring Mutations in Myelodysplastic Syndromes Pathogenesis.
Matos A; Magalhães SMM; Rauh MJ
Adv Exp Med Biol; 2021; 1326():1-10. PubMed ID: 33385175
[TBL] [Abstract][Full Text] [Related]
20. Intrinsic growth deficiencies of mesenchymal stromal cells in myelodysplastic syndromes.
Aanei CM; Flandrin P; Eloae FZ; Carasevici E; Guyotat D; Wattel E; Campos L
Stem Cells Dev; 2012 Jul; 21(10):1604-15. PubMed ID: 21933023
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
